Media headlines about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1742770045201 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Fate Therapeutics, Inc. (FATE) Stock Active volume Figures at Street – Investing News Update (investingbizz.com)
- Fate Therapeutics (FATE) Reports Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune (streetinsider.com)
- Fate Therapeutics (FATE) Stock Rating Reaffirmed by HC Wainwright (americanbankingnews.com)
- Fate Therapeutics, Inc. (NASDAQ:FATE) – Is The Stock A Good Investment? – Nasdaq Journal (nasdaqjournal.com)
- HC Wainwright Keeps a Hold Rating on Fate Therapeutics – Analyst Ratings (analystratings.com)
FATE stock opened at $10.92 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 9.29 and a current ratio of 9.29. The company has a market cap of $617.43, a price-to-earnings ratio of -10.71 and a beta of 1.65. Fate Therapeutics has a 12 month low of $2.52 and a 12 month high of $14.45.
A number of research firms have recently weighed in on FATE. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Friday, January 19th. BidaskClub raised Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 23rd. HC Wainwright reaffirmed a “hold” rating and set a $12.00 price objective on shares of Fate Therapeutics in a research report on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Fate Therapeutics in a research report on Monday, December 18th. Finally, UBS lowered Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $13.71.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3294765/fate-therapeutics-fate-receives-daily-media-sentiment-score-of-0-18.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.